NightHawk’s Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New Client
16 janv. 2024 08h30 HE
|
NightHawk Biosciences
DURHAM, N.C., Jan. 16, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO),...
NightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Transition to a Large Molecule Biomanufacturing CDMO
08 janv. 2024 08h30 HE
|
NightHawk Biosciences
DURHAM, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK; NHWK), an integrated contract development and manufacturing organization (CDMO), today announced that it...
NightHawk Biosciences Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement For a Leading National University
03 janv. 2024 08h30 HE
|
NightHawk Biosciences
DURHAM, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO),...
NightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research University
21 déc. 2023 08h30 HE
|
NightHawk Biosciences
Next phase of multi-million-dollar project to include scaling up cGMP manufacturing for phase 1 trial targeting infectious disease CDMO services attracting considerable interest as...
NightHawk Biosciences Announces Major Milestone with Completion of Manufacturing Run for a Premier U.S.-Based Biopharmaceutical Company
18 déc. 2023 08h30 HE
|
NightHawk Biosciences
Manufacturing run at Scorpius’ state-of-the-art San Antonio microbial facility sets the stage for commercial manufacturing Advances multi-million dollar biomanufacturing contract awarded earlier this...
NightHawk Biosciences Announces Strategic Shift into a Pure-Play Large Molecule Biomanufacturing CDMO to Capitalize on Rapid Growth in Sales Pipeline along with Divestiture of Non-Core Assets
12 déc. 2023 08h30 HE
|
NightHawk Biosciences
Over $20 million in signed manufacturing contracts which includepremier biotech/pharma companies and research institutes Elusys divestiture and R&D cuts expected to eliminate over $40 million...
NightHawk Biosciences Provides Q3 2023 Business Update
20 nov. 2023 16h05 HE
|
NightHawk Biosciences
DURHAM, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing,...
NightHawk Biosciences Provides Q2 2023 Business Update
14 août 2023 16h05 HE
|
NightHawk Biosciences
DURHAM, N.C., Aug. 14, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing,...
NightHawk Biosciences Provides Q1 2023 Business Update
15 mai 2023 16h05 HE
|
NightHawk Biosciences
DURHAM, N.C., May 15, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing,...
NightHawk Biosciences Provides 2022 Year End Business Update
31 mars 2023 16h05 HE
|
NightHawk Biosciences
DURHAM, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate...